Stifel Financial Corp Sells 5,936 Shares of Genmab A/S (NASDAQ:GMAB)

Stifel Financial Corp lessened its holdings in Genmab A/S (NASDAQ:GMAB) by 3.4% in the third quarter, Holdings Channel reports. The institutional investor owned 168,991 shares of the company’s stock after selling 5,936 shares during the period. Stifel Financial Corp’s holdings in Genmab A/S were worth $4,120,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in GMAB. DDD Partners LLC bought a new position in shares of Genmab A/S during the second quarter valued at $8,860,000. Cubist Systematic Strategies LLC increased its holdings in Genmab A/S by 109.7% in the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock valued at $7,000,000 after purchasing an additional 145,689 shares during the period. Renaissance Technologies LLC raised its position in Genmab A/S by 7.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after purchasing an additional 103,859 shares during the last quarter. Sanctuary Advisors LLC acquired a new position in Genmab A/S during the 2nd quarter worth about $1,354,000. Finally, Ingalls & Snyder LLC grew its position in shares of Genmab A/S by 29.3% in the 2nd quarter. Ingalls & Snyder LLC now owns 229,700 shares of the company’s stock valued at $5,772,000 after buying an additional 52,117 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GMAB has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research report on Wednesday, October 16th. Redburn Atlantic initiated coverage on shares of Genmab A/S in a research report on Tuesday, October 8th. They issued a “buy” rating on the stock. Truist Financial decreased their price objective on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, September 9th. Morgan Stanley restated an “equal weight” rating and issued a $31.00 target price on shares of Genmab A/S in a report on Wednesday, September 11th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Stock Down 2.3 %

Shares of GMAB stock opened at $20.17 on Monday. The firm has a 50 day moving average of $22.15 and a 200-day moving average of $25.05. The company has a market cap of $13.35 billion, a price-to-earnings ratio of 19.58, a price-to-earnings-growth ratio of 0.67 and a beta of 0.96. Genmab A/S has a 52 week low of $20.12 and a 52 week high of $32.88.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The company had revenue of $816.10 million during the quarter, compared to analyst estimates of $838.20 million. During the same quarter in the previous year, the business posted $0.47 earnings per share. Analysts anticipate that Genmab A/S will post 1.28 earnings per share for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.